[A23-56] Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V

Last updated 15.09.2023

Project no.:

Commission awarded on 14.06.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Heart and circulation


Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction

Result of dossier assessment:

Added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form